Peptides
Beyond Diabetes: The Expanding—and Uneasy—Frontier of GLP-1 Medicine
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.